Company Overview
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Why Investors Should Care
Revenue has grown at a 37.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $747.14M (+26.2% YoY); net profit $-44.55M.
- Trailing 12 Months Year-on-year growth — revenue +25.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 37.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 37.92% |
| 1 Year: | 25.70% |
Stock Price Performance
| 1 Year: | -18.47% |
| 6 Months: | -32.98% |
| 3 Months: | -8.09% |
| 1 Month: | -0.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 37.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 40.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRTC iRhythm Holdings, Inc. R2K | 113.26 | -133.25 | $3.72B | 0.00% | -6.61% | -22.42% | 37.92% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 21.44M | 23.85M | 25.04M | 28.18M | 31.76M | 35.29M | 38.44M | 41.78M | 48.33M | 52.44M | 54.67M | 59.10M | 63.53M | 50.88M | 71.94M | 78.81M | 74.31M | 81.28M | 85.43M | 92.38M | 102.05M | 103.88M | 111.44M | 124.13M | 124.60M | 131.93M | 148.05M | 147.54M | 158.68M | 186.69M | 192.88M | 199.39M |
| Gross Profit | 3.88M | 5.27M | 5.60M | 6.69M | 8.20M | 10.58M | 11.50M | 12.92M | 15.10M | 17.11M | 18.11M | 20.48M | 23.21M | 25.81M | 28.49M | 30.98M | 36.56M | 39.43M | 40.89M | 45.19M | 47.47M | 35.39M | 53.71M | 58.31M | 50.85M | 55.28M | 56.15M | 61.76M | 70.25M | 70.92M | 75.68M | 86.22M | 82.47M | 87.52M | 103.47M | 101.48M | 109.22M | 132.86M | 137.12M | 141.35M |
| Operating Income | - | - | -5.50M | - | -4.87M | -3.70M | -2.67M | - | -4.75M | -5.92M | -5.98M | - | -10.60M | -12.78M | -9.22M | - | -8.20M | -10.56M | -18.26M | - | -9.17M | -20.16M | -4.76M | - | -27.47M | -16.99M | -23.28M | -48.55M | -23.45M | -21.09M | -39.50M | -18.87M | -27.60M | -38.14M | -22.98M | -50.30M | -32.56M | -18.71M | -8.43M | -16.18M |
| Net Income | -4.39M | -4.96M | -5.75M | -7.70M | -6.13M | -4.44M | -4.08M | -6.27M | -5.30M | -6.44M | -6.52M | -11.15M | -11.08M | -13.30M | -9.73M | -16.27M | -8.25M | -10.72M | -18.29M | -17.30M | -9.06M | -20.44M | -4.68M | -9.65M | -27.78M | -17.36M | -23.73M | -50.61M | -23.90M | -21.45M | -39.11M | -18.48M | -27.12M | -45.67M | -20.11M | -46.18M | -30.70M | -14.22M | -5.21M | -13.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.75 | -0.17 | - | -0.95 | -0.59 | -0.81 | -1.71 | -0.80 | -0.71 | -1.29 | -0.61 | -0.89 | -1.47 | -0.65 | -1.48 | -0.97 | -0.44 | -0.16 | -0.43 |
| R&D Expense | - | - | 1.65M | - | 1.54M | 1.67M | 1.64M | - | 2.62M | 2.78M | 3.79M | - | 4.04M | 4.65M | 5.09M | - | 6.70M | 7.83M | 13.50M | - | 8.41M | 12.54M | 8.77M | - | 8.51M | 9.61M | 8.69M | 10.54M | 11.95M | 11.45M | 14.84M | 13.68M | 16.31M | 16.99M | 19.69M | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.75M | 36.14M | 64.07M | 99.13M | 147.28M | 214.55M | 265.17M | 322.82M | 410.92M | 492.68M | 591.84M | 747.14M |
| Gross Profit | 11.16M | 21.44M | 43.19M | 70.93M | 108.48M | 162.07M | 194.89M | 213.57M | 281.63M | 331.81M | 407.53M | 527.25M |
| Operating Income | -14.77M | -21.63M | -15.58M | -27.59M | -45.69M | -54.76M | -43.67M | -99.94M | -113.78M | -125.16M | -115.50M | -57.41M |
| Net Income | -15.83M | -22.80M | -20.90M | -29.74M | -50.38M | -54.57M | -43.83M | -101.36M | -116.16M | -123.41M | -113.29M | -44.55M |
| Diluted EPS | - | - | - | - | - | -2.16 | -1.58 | -3.46 | -3.88 | -4.04 | -3.63 | -1.39 |
| R&D Expense | 5.70M | 6.35M | 7.15M | 13.27M | 20.86M | 37.30M | 41.33M | 38.67M | 46.61M | 60.24M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.87M | 138.16M | 133.12M | 117.52M | 306.21M | 511.74M | 462.97M | 448.22M | 433.14M | 931.45M | 1.02B |
| Total Equity | -65.59M | -80.54M | -101.62M | 93.04M | 79.34M | 52.14M | 135.41M | 341.61M | 279.51M | 239.81M | 210.10M | 90.91M | 152.75M |
| Cash & Equivalents | 7.10M | 8.62M | 25.21M | 51.64M | 8.67M | 20.02M | 20.46M | 88.63M | 127.56M | 78.83M | 36.17M | 419.60M | 236.01M |
| Long Term Debt | - | - | 30.55M | 32.23M | 32.49M | 34.90M | 32.99M | 21.34M | 9.69M | 34.94M | 34.95M | - | - |
| Total Liabilities | - | - | 42.40M | 45.59M | 53.57M | 65.39M | 170.80M | 170.13M | 183.45M | 208.41M | 223.05M | 840.54M | 867.30M |
| Current Liabilities | - | - | 8.78M | 13.21M | 20.92M | 30.33M | 52.07M | 65.67M | 87.85M | 89.10M | 107.37M | 110.92M | 151.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -16.65M | -14.91M | -29.09M | -21.86M | -13.76M | -37.75M | -23.01M | -50.10M | 3.39M | 80.86M |
| Investing Cash Flow | - | - | -68.17M | -34.68M | 34.14M | -89.27M | -132.39M | 105.26M | -52.43M | -1.21M | -122.98M | -277.06M |
| Financing Cash Flow | - | - | 111.25M | 6.53M | 6.30M | 111.58M | 214.32M | -28.58M | 26.72M | 8.82M | 511.38M | 12.61M |
| Capital Expenditure | -539.00K | -1.79M | -2.76M | -3.56M | -5.18M | -20.46M | -13.55M | -28.07M | -29.83M | -40.42M | -33.94M | -46.34M |
| Free Cash Flow | - | - | -19.41M | -18.47M | -34.27M | -42.32M | -27.31M | -65.82M | -52.84M | -90.53M | -30.55M | 34.52M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 0 | 25.00M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.3% | 59.3% | 67.4% | 71.5% | 73.7% | 75.5% | 73.5% | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% |
| Operating Margin % | -67.9% | -59.9% | -24.3% | -27.8% | -31.0% | -25.5% | -16.5% | -31.0% | -27.7% | -25.4% | -19.5% | -7.7% |
| Net Margin % | -72.8% | -63.1% | -32.6% | -30.0% | -34.2% | -25.4% | -16.5% | -31.4% | -28.3% | -25.0% | -19.1% | -6.0% |
| ROE % | 19.7% | 22.4% | -22.5% | -37.5% | -96.6% | -40.3% | -12.8% | -36.3% | -48.4% | -58.7% | -124.6% | -29.2% |
| ROCE % | - | -74.3% | -12.5% | -24.6% | -52.4% | -21.5% | -9.8% | -26.6% | -31.7% | -38.4% | -14.1% | -6.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRTC
iRhythm Holdings (IRTC) Following Zio And AI Growth Narrative Faces A Valuation Question - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPQXViaS1RaFBpTHY5SFFhNFdYUW0tNjVaVUwzMVVISDcyS2xuZWNrZ1FmZUdVaTdoTW8wTGtsUGpNc0RSajIyOTBBdWRHZ1VxT08xVXhTTmlBZ2k1eFFzcnYxMm1BNzdOSTFYbDlGMVlpMTJvYkladm8xOEpoU01QYzhRRkkyTHJCdlItaH…
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxQS0p4WFJfTUlPcjBoWmZkQi00Rl9WVW5FUHM1ZTlielNNUHdYX2tGNmczZ3NuUEtvNENtVmxKNFhtcS16eDhSXzhFenpZUXdUVWlLVUlybXZLS2RIXzU2RkpwRjhTcTRVUzJLaDlBbXQ0TnlsaU9uVG1RcW02bmJrb2xFdjIwelFpYWtJVm…
IRTC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9jbXgtS0d3VXJYc3dpcHVjMGNsWVZwa3ZGRE9yUXZ4Rk9ydGxtRHlXX2swTWtkMC04aWRKaUVfbmJaTjd3UXZEYmd6MDdQWVNybUxNd2hQS20ycGo4VmVLd05nLUxRdmYzWGN2RGVUN3Y4d21zcjNPbHpR?oc=5" target="_blank">IRT…
iRhythm Holdings (IRTC) Dropped Despite Posting Beat-And-Raise Results - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOd3l5WVVESDgzcHZUMUhmeFpneVpIVHpSZGo1MU00REI1LXBLMXl0bnZZT25TVFNuWEthZkN0cXgtc3pnYXRkS1U0V2RPMmR4THlya3huVnd6ZlNIajVtV1l4NHM3aHJGMWxBaE9xaFQtTUxnaHhxbXQ3MkUzRThsUTVkX0tzR3l2NnFNM1…
iRhythm (IRTC) Removed from Conviction List but Rating Remains P - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQOTJlc0ZWU2wtcmJpQzNSZnZOd3o0aUgwa0NaUy1iTXlZWE8zUXhsck5fVEJhZzE1MUdYZ2l4bnlVaXNhVU9FZWlGQ2dpaGRuSVE5MWplQmxWWXhoZEZqSU9ZcTZsclc5d1dHZm5uS1E3al9xMG1MQjAzTkc0U2pRQ1ZGV0RHVjZIb1VDNm…
IRhythm Holdings, Inc. (IRTC) Stock Analysis: A 41% Potential Upside Beckons Investors - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPOEVkei1rMjZrdU1qdWtKMktSdG5PR1ViZjRXd2Q1THlRVjNfSmYxbmVWaGswY0JIbnUxcEFNczFCT21qVV8zLVE5MnFxQzgxNnhwT0MxQy1hLVZqdEYxTVY4MTlKX1VYWVpzS0FaczdvWXhwejI5dUh4NW9pMmFrVXBjdkt3dmlsSGdKdm…
IRTC — Frequently Asked Questions
What is the current share price of iRhythm Holdings, Inc. (IRTC)?
As of 2026-07-15 16:51 PDT, iRhythm Holdings, Inc. (IRTC) trades at $113.26 on NasdaqGS. Its 52-week range is $101.79 to $189.25.
What is the market capitalisation of IRTC?
iRhythm Holdings, Inc. (IRTC) has a market capitalisation of $3.72B on NasdaqGS.
What is the P/E ratio of IRTC?
IRTC trades at a trailing price-to-earnings (P/E) ratio of -133.25. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 23.16.
What is the return on equity (ROE) of IRTC?
IRTC has a return on equity (ROE) of -22.42%. Its return on capital employed (ROCE) is -6.61%.
Is IRTC a good stock to buy?
This page provides a data-driven analysis of iRhythm Holdings, Inc. (IRTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.